BioMarin Pharmaceutical Inc. announced today that its partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has received marketing approval for Kuvan(R) (sapropterin dihydrochloride)...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Piper Jaffray Healthcare Conference in New York...

BioMarin Pharmaceutical Inc. today announced that Dr. Emil Kakkis, its Chief Medical Officer will retire from the company on February 27, 2009. Dr. Kakkis has decided to leave his position with...

BioMarin Pharmaceutical Inc. announced today that data from clinical studies of Kuvan(R) (sapropterin dihydrochloride), Naglazyme(R) (galsulfase) and enzyme replacement therapies for MPS IVA...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Credit Suisse 2008 Annual Healthcare Conference...

BioMarin Pharmaceutical Inc. announced today the initiation of the Morquio Clinical Assessment Program (MorCAP) for patients with the lysosomal storage disease Mucopolysaccharidosis Type IVA (MPS...

Financial Highlights ($ in millions, except per share data) Item Q3 2008 Q3 2007 Comparison Total BioMarin Revenue $72.6 190.5% increase Naglazyme Net Product Revenue $33.3 56.3% increase...

BioMarin Pharmaceutical Inc. today announced results from its Phase 2a multi-center, open-label, dose-escalation clinical study of 6R-BH4 in patients with sickle cell disease (SCD) designed to...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, October 28, at 5:00 p.m. ET (23:00...

BioMarin Pharmaceutical Inc. announced today that it has opened a new office in Brisbane, California, to expand its drug development operations and better meet the increasing demands of the...

BioMarin Pharmaceutical Inc. announced today that its partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has received a positive opinion for Kuvan(R) (sapropterin dihydrochloride)...

BioMarin Pharmaceutical Inc. announced today several corrections to an article released by Bloomberg this morning. The article was based on a telephone interview with Jean-Jacques Bienaime, Chief...

BioMarin Pharmaceutical Inc. today announced that Joshua Grass, Vice President of Business and Corporate Development of BioMarin, will present a company update at the Merrill Lynch Global...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Morgan Stanley Global Healthcare Conference in...

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 3rd Annual Citi Biotech Day in New York City on...

BioMarin Pharmaceutical Inc. announced today the roll-out of the national PKU Demographics, Outcomes and Safety Registry (PKUDOS). The registry is open to all PKU clinics within the United States,...

Financial Highlights ($ in millions, except per share data) Item Q2 2008 Q2 2007 Comparison Total BioMarin Revenue $64.2 122% increase Naglazyme Net Product Revenue $35.1 67.9% increase Aldurazyme...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and Summit Corporation plc (AIM: SUMM) announced today that they have entered into an exclusive worldwide licensing agreement for Summit's novel...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Asubio Pharma Co., Ltd. (a subsidiary of Daiichi Sankyo), has received marketing approval from the Japanese Ministry of...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, August 5,...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin, will present a company update at the Collins Stewart Growth...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced its program for its third enzyme replacement therapy (ERT) for the treatment of mucopolysaccharidosis IVA (MPS IVA), or Morquio...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) will host a Research and Development Day for the financial community on Thursday, June 5, 2008 from 7:30 a.m. to 11:30 a.m. at the W New York...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that the first patient has initiated treatment in the Phase 1 clinical study of PEG-PAL (PEGylated recombinant phenylalanine...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Bank of America Healthcare...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Stephen Aselage, Senior Vice President of Global Commercial Development of BioMarin, will present a company update at the...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced financial results for the first quarter ended March 31, 2008. Net income was $1.7 million ($0.02 per share) for the first...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin, will present a company update at the Morgan Stanley Global...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, April 29,...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that AnGes MG, Inc. (AnGes), BioMarin's marketing and distribution partner in Japan, has received approval for its Marketing...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Lehman Brothers Global...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Stephen Aselage, Senior Vice President of Global Commercial Development of BioMarin, will present a company update at the...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jeff Cooper, Chief Financial Officer of BioMarin, will present a company update at the Cowen and Company 28th Annual...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced financial results for the fourth quarter and full year ended December 31, 2007. Net income was $2.6 million ($0.03 per share)...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, February...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the 19th Annual Merrill Lynch...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today the appointment of Dr. Gordon Vehar as Vice President of Research. Former Vice President of Research and Development for Raven...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Wachovia Healthcare...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has appointed Mr. Steve Glass as Vice President and General Manager of European Operations. BioMarin Europe Ltd.,...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and Genzyme Corporation announced today a restructuring of their joint venture regarding Aldurazyme(R) (laronidase). Under the revised...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has re-acquired the Canadian rights for tetrahydrobiopterin (BH4), including Kuvan(TM) (sapropterin dihydrochloride),...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Kuvan(TM) (sapropterin dihydrochloride)...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and IGAN Biosciences announced today that they have initiated a program to develop an IgA protease for treating IgA nephropathy. IgA proteases...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for PEG-PAL...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that its partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has submitted the Marketing Authorization...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Credit Suisse Annual...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced financial results for the third quarter ended September 30, 2007. The net loss was $5.2 million ($0.05 per share) for the third...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin, will present a company update at the Rodman & Renshaw 9th...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has provided a $250,000 grant to the National Organization for Rare Disorders (NORD) to support a new financial...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, November...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that data from clinical studies of Kuvan(TM) (sapropterin dihydrochloride), Naglazyme(R) (galsulfase), and Aldurazyme(R)...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that a systematic literature review and meta-analysis of blood phenylalanine (Phe) levels and clinical outcomes in...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has licensed to Asubio Pharma Co., Ltd. (a subsidiary of Daiichi Sankyo) exclusive rights to data and intellectual...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin, will present a company update at the Bear Stearns 20th Annual...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the BioCentury NewsMakers in...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has licensed from the University of California, San Francisco (UCSF) intellectual property covering compounds...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that AnGes MG, Inc. (AnGes), BioMarin's marketing and distribution partner in Japan, has submitted a Biologics License...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that final results from the Kuvan(TM) (sapropterin dihydrochloride) pivotal Phase 3 clinical trial were published in the August...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced financial results for its second quarter ended June 30, 2007. The net loss was $3.9 million ($0.04 per share) for the second...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and granted priority review status to the New Drug...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, August 7,...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that the first patient has initiated treatment in the expanded access program for Kuvan(TM) (sapropterin dihydrochloride), an...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the NASDAQ 19th Investor...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Bank of America Health...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Kuvan(TM) (sapropterin...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Citigroup Global...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Rodman & Renshaw 4th...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin, will present a company update at the Baird Growth Stock...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that the first patient has initiated treatment in the Phase 2a clinical study of 6R-BH4 (sapropterin dihydrochloride) for the...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced financial results for its first quarter ended March 31, 2007. The net loss was $9.3 million ($0.10 per share) for the first...

BioMarin Pharmaceutical Inc. announced today that it closed the sale of $324,875,000 aggregate principal amount of its 1.875% Senior Subordinated Convertible Notes due 2017 (including $42,375,000...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, May 2, at...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has agreed to sell $282.5 million aggregate principal amount of its 1.875% senior subordinated convertible notes due...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it intends to offer to sell, subject to market and other conditions, $250 million aggregate principal amount of senior...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Lehman Brothers Tenth...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Cowen and Company 27th...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced results from its Phase 2a placebo-controlled double-blind study of 6R-BH4 in patients with poorly controlled hypertension....

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced financial results for its fourth quarter and year ended December 31, 2006. The net loss was $10.4 million ($0.11 per share) for...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that it has changed the date and time of its fourth quarter and full year 2006 financial results conference call and webcast...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Merrill Lynch Global...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that in response to the previously announced call for redemption of its remaining $51.4 million aggregate principal outstanding...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced positive results from the Phase 3 diet study of Phenoptin(TM) (sapropterin dihydrochloride), in combination with diet, in 4-12...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the JPMorgan 25th Annual...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that the first patient has initiated treatment in the Phase 2 clinical study of 6R-BH4 for the treatment of symptomatic...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) gave formal notice today that it is calling for redemption on January 26, 2007 (the Redemption Date), the remainder of its outstanding 3.50%...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced positive results from the pivotal Phase 3 extension study of Phenoptin (sapropterin hydrochloride), an investigational oral...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin, will present a company update at the Cowen and Company 7th...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced results for its third quarter ended September 30, 2006. The net loss was $7.0 million ($0.08 per share) for the third quarter of...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Rodman and Renshaw 8th...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Japan's Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for Aldurazyme(R) (laronidase),...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that 4 holders of its 3.50% Convertible Senior Subordinated Notes due 2008 have agreed to exchange $73.6 million in aggregate...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it has completed enrollment of the Phase 2 clinical study of 6R-BH4 for the treatment of poorly controlled hypertension....

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) and Serono (virt-x: SEO and NYSE: SRA) today announced data from clinical studies of Phenoptin(TM) (sapropterin dihydrochloride), an...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that investigators presented data from preclinical studies of Phenylase(TM) (phenylalalanine ammonia lyase) that suggest the...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at BioCentury's NewsMakers in the...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Thomas Weisel Partners...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that Orapred ODT(TM) (prednisolone sodium phosphate orally disintegrating tablets), the first FDA-approved orally disintegrating...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced results for its second quarter ended June 30, 2006. The net loss was $1.3 million ($0.02 per share) for the second quarter of...

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that the first patient has initiated treatment in the Phase 2 clinical study of 6R-BH4 for the treatment of poorly controlled...